Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6373120 | 0.89 | MAOB (0.62) | MAOBMEN1KMT2AMAPK1POLB | |
| SCHEMBL6374745 | 0.84 | LIPE (0.55) | MEN1KMT2ALMNAHTTALDH1A1 | |
| SCHEMBL14158144 | 0.81 | ESR1 (0.54) | MAOBPOLBALDH1A1 | |
| SCHEMBL6376059 | 0.79 | HDAC3 (0.57) | MAOBMEN1KMT2AMAPK1POLB | |
| SCHEMBL30109340 | 0.79 | LIPE (0.58) | MEN1KMT2AMAPK1LMNAMAPT | |
| SCHEMBL2972419 | 0.79 | NMT1 (0.54) | MAOBMEN1KMT2AMAPK1POLB | |
| SCHEMBL19284497 | 0.78 | ALDH1A1 (0.49) | MAOBMEN1KMT2APOLBMAPT | |
| SCHEMBL27343430 | 0.76 | MAOB (0.74) | MAOBMEN1KMT2AMAPK1LMNA | |
| SCHEMBL17869278 | 0.76 | NPC1 (0.58) | MEN1KMT2AMAPTHTTALDH1A1 | |
| SCHEMBL28138226 | 0.76 | MAOB (0.73) | MAOBMEN1KMT2AMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| WO-2003068807-A2 | ECHINOCANDIN CYCLIC PEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050181988-A1 | Echinocandin cyclic peptide derivatives | NGLY1, ARG1, ERG28 | MAOB 4833/4885MEN1 1139/4885KMT2A 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.